Of 12 patients with the diagnosis of a malignant tumor by needle biopsy, 11 had surgery performed, and 1 was treated with chemotherapy because it was an advanced case. Two advanced cases were treated with surgery after chemotherapy. Surgery specimens were classified as LMS (n = 10) and endometrial stromal sarcoma (n = 1). Of 51 patients with the diagnosis of benign tumors, 27 underwent a hysterectomy or myomectomy. After the surgery, the condition of 1 of the 27 patients was diagnosed with a low-grade endometrial stromal sarcoma, and the other 26 were diagnosed with a leiomyoma.
Twenty-four patients were managed conservatively, being observed every 3 months according to their symptoms. Tumor and uterine sizes were measured by ultrasonography at each visit. These 24 patients lacked any evidence of uterine malignancy during subsequent follow-ups.
In the 38 cases where surgery was performed, the sensitivity and specificity of the biopsy diagnosis was 91.7% and 100%, respectively. The positive predictive value of the biopsy was 100%, and the negative predictive value was 96.2%. We had 2 cases of infection that needed surgery to control. Both cases were LMS with widespread necrosis. Other than these 2 cases, no major complications, such as intraperitoneal hemorrhage or injury to adjacent structures that required surgery, were observed.
To treat a uterine tumor properly without doing unnecessary surgery, differentiating uterine sarcomas from benign leiomyomas is very important. The MRI is an important tool for diagnosing uterine tumors. The typical MRI appearance of an LMS reveals a heterogeneous appearance with intermediate to high signal intensity on T2-weigted images and enhances well. In a typical case, MRI reveals high intensity on T1-weigted images with coagulated tumor necrosis.8 Confeld et al9 reported finding a distribution of imaging criteria between leiomyoma and other mesenchymal neoplasms. Objective criteria included T1 and T2 signal characteristics, enhancement pattern, the presence of cystic changes, and an ill-defined margin.9 However, in a previous report of patients with findings of coagulative tumor cell necrosis, the incidence of LMS was limited to 68%, and in the 5% of the patients without findings of coagulative tumor cell necrosis, LMS was noted.4 There are many case reports that had few of these typical imaging characteristics. On the other hand, there is also 1 report claiming that malignant tumors were rare in cases that were operated on solely because they seemed to be rapidly growing.10
Recently, by using diffusion-weighted MRI, it became possible to perform diagnoses that are more detailed.11 We performed our very first uterine DWI in September 2008. From January 2010 onward, we performed DWI for all such cases. Namimoto et al12 reported that ADC combined with T2-weigted imaging is significantly better than ADC or T2-weighted imaging alone at differentiating between sarcomas and leiomyomas. However, there are limitations to their study; the number of sarcomas was relatively small, and some leiomyomas were not proven diagnostically.12
In 2002, Kawamura et al reported obtaining good diagnostic results using a transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma.7 They reported that a transcervical needle biopsy, using a histopathological scoring system that was established based on the criteria proposed by Bell et al,8 is highly precise, with an especially high negative predictive value.
By performing a needle biopsy, we can diagnose whether the uterine mass is a benign or malignant tumor. As a result, we can avoid unneeded surgery in cases with a poor general status or distant metastasis, or do only limited procedures, such as fertility-sparing surgery, laparoscopic surgery, or transvaginal surgery.
In addition to it, DWI reduced the cases that needed needle biopsy. So we have performed needle biopsy with limited cases in recent years.
In our report, although the exact number of uterine tumors with high or undetermined T2-weighed MRI signal between January 2005 and August 2012 is unclear, we could recruit 63 cases for needle biopsy. Of those 63 cases, 13 cases turned out to be sarcomas. On the other hand, a total of 41 uterine sarcomas were treated in our hospital during that period. Therefore 13 (31%) of 41 uterine sarcomas were biopsied as a consequence. Because conducting the needle biopsy provided a correct differential diagnosis, 24 of the 63 cases were able to avoid an unneeded operation altogether, 7 had laparoscopic surgery, and 4 had transvaginal surgery.
We only targeted tumors with high intensity T2 signal on MRI. On the other hand, there were no malignant cases among 51 patients with a low intensity T2 signal. We had suspected that these were malignant tumors because of their rapid growth or because they had hemorrhagic necrosis. Among the 46 patients who were not strongly suspected of having a malignant tumor (because they were only high signal intensity on T2-weighted images), there were 2 atypical cases of malignant tumor that were then diagnosed as malignant tumor by needle biopsy.
We evaluated 18 patients with DWI; in the group of 11 patients who had increases in DWI and decreases in ADC, there were 4 malignant tumors; in the 7 patients who had an increase DWI but no decrease in ADC, there were no malignant tumors. There is now the strong possibility that we can perform a needle biopsy more efficiently by restricting its use to patients with tumors that have a high signal with T2-weighted DWI imaging and a low signal with ADC.
One of the possible critical drawbacks of doing a needle biopsy is the possibility of spreading cancer cells. In the 12 tumor cases where we performed surgery after the needle biopsy, the median number of days from biopsy to surgery was 37.5 days (range, 10–113 days); in this cohort, there was no evidence that conducting the biopsy had spread the cancer. In cases where we strongly suspected a malignancy by MRI, we first evaluated with computed tomography whether there were distant metastases before conducting the needle biopsy. In 5 advanced cases, the computed tomography pointed out the presence of metastatic sites before the needle biopsy.
When performing a needle biopsy, there can be problems with accurate sampling, such as difficulties with the specimens, the diagnostic accuracy of any microsample, and the frequency of postbiopsy complications. In our report, 3 of the 68 specimens (4.8%) were difficult to diagnose; 1 was too small, and 2 consisted of only necrotic material. One patient underwent repeated ultrasound-guided needle biopsies and was with diagnosis of a malignant tumor. In another patient, repeating the biopsy was difficult because of an infection, and her condition was diagnosed after surgery with an LMS. Two other patients who underwent repeated biopsies did not undergo surgery because a malignant tumor was not strongly suspected.
In our research, the negative predictive value of the biopsy was 96.2%. There was 1 case in which the postsurgical diagnosis of a low-grade endometrioid stromal sarcoma (ESS) was different than by needle biopsy, which had suggested it was a leiomyoma. The existence of invasion is important for the distinction of an ESS from a benign tumor, and such invasion may be difficult to determine in a biopsy specimen.
There are numerous reports of cases simultaneously having leiomyoma and LMS. Mittal and Joutovsky reported that a spectrum of morphologic and immunohistochemical changes, from benign to malignant, is seen in 50% of LMSs, indicative of the progression of some leiomyoma to LMS.13 Thus, when an unambiguous nodule is present within a myoma, we should bear in mind the possibility of the presence of a malignancy.
In our report, there were 2 cases of infection associated with an LMS with widespread necrosis. When we performed the needle biopsy on these cases, we had to consider carefully which area to perform the biopsy on and which type of patient management to conduct afterward.
Except in cases of low-grade malignancy, a presurgical guided needle biopsy for difficult cases may generally be as useful as a postsurgical histological examination of the tumor. Thus, we have found that in cases where a uterine malignancy is suspected by MRI, a preoperative needle biopsy is a highly effective tool for determining that most such cases are benign, a result which greatly expands our ability to use more conservative and appropriate treatment options.
On the other hand, there are complications, such as infection, that can occur from conducting a needle biopsy. It is also important to take into consideration that there will be rare cases that are just too difficult to diagnose by needle biopsy, that there may be the possibility of cancer spread after biopsy, and that malignancy can never be 100% ruled out by this means. We are thus ethically required to be selective of the cases we chose to diagnose in this manner.
There are now several other presurgical treatment options that can greatly benefit the patient. Examples are administering chemotherapy or molecular-targeted drugs, conducting radiotherapy, or induction of arterial embolism in the tumor. Going forward, a guided needle biopsy will help us choose which of these nonsurgical treatment plans is most appropriate for our patients.
1. McMeekin DS. Sarcoma of the uterus. In: Di Saia PJ, Creasman WT, eds. Clinical Gynecologic Oncology
. 8th ed. St Louis, MO: Elsevier Saunders; 2012: 175–187.
2. Leibsohn S, D’Ablaing G, Mishell DR Jr, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol
. 1990; 162: 968–974.
3. Aviram R, Ochshorn Y, Markovitch O, et al. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings. J Clin Ultrasound
. 2005; 33: 10–12.
4. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography using 2-[18F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report. Clin Imaging
. 2001; 25: 203–205.
5. Yoshida Y, et al. Additional value of 16α[18F] fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F] fluorodeoxyglucose PET. Eur J Nucl Med Mol Imaging
. 2011; 38: 1824–1831.
6. Kawamura N, Ichimura T, Takahashi K, et al. Transcervical needle biopsy of uterine myoma-like tumors using an automatic biopsy gun. Fertil Steril
. 2002; 77: 1060–1064.
7. Kawamura N, Ichimura T, Ito F, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer
. 2002; 94: 1713–1720.
8. Bell S, Kempson R, Hendrickson M. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol
. 1994; 18: 535–558.
9. Confeld D, et al. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol
. 2010; 74: 241–249.
10. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol
. 1994; 83: 414–418.
11. Tamai K, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol
. 2008; 18: 723–730.
12. Namimoto T, et al. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging differentiating uterine sarcomas from benign leiomyomas. Eur Radiol
. 2009; 19: 2756–2764.
13. Mittal K, Joutovsky A. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol
. 2007; 104: 362–365.
Keywords:© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.
Uterine tumor; Needle biopsy; Sarcoma; Leiomyoma; Diffusion-weighted MRI